CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI)

CASI stock results show that CASI Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

Healthcare innovations are big business. That said, biotech stocks under $10 may offer a higher ceiling thanks to their low price.

Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to support its portfolio of drugs.

Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning!

CASI stock results show that CASI Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

CASI stock results show that CASI Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

CASI Pharmaceuticals and BioInvent share promising results for BI-1206 in treating relapsed/refractory indolent Non-Hodgkin's Lymphoma patients in China. Preliminary data reveals clinical efficacy with partial and complete responses, affirming positive safety profiles.

LianBio, a Princeton-Shanghai biotech, has decided to call it quits. LianBio plans to stop all of its operations by the end of 2024, and it will distribute a $4.80 dividend/share ($528 million) to its shareholders.

Gainers

Pre-market stock movers are a hot topic on Wednesday morning and we're covering all of the latest news investors need to know about!

Mundipharma is considering selling its China operations in a deal that could be worth $1 billion. Additionally, Oramed Pharma plans to form a $60 million JV with Hefei Tianhui Biotech to commercialize Oramed's oral drug delivery products globally.